Background Safe and effective vaccines against COVID-19 are critical for preventing the
spread of SARS-CoV-2, but little is known about the humoral immune response more than 9 …

Background Real-world population studies have shown waning immunity, over time, after
receiving the two doses of the BNT162b2 COVID-19 vaccine. Studies reporting the long …

Background There is preliminary evidence that individuals with previous SARS‐CoV‐2
infections exhibit a more pronounced antibody response. However, these assumptions have …

Objectives: Reliable evidence suggests that anticipating the humoral response to
coronavirus disease 2019 (COVID-19) vaccines is essential for predicting their clinical …

Background A third dose of the BNT162b2 SARS-CoV-2 vaccine leads to a significant
increase in antibody levels, however, concerns regarding the long-term persistence of this …

Background: Studies reporting the long-term humoral response after receiving the
BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet …

Background: Vaccination is one of the most effective life-saving medical interventions, and
the introduction of SARS-CoV-2 vaccines was intended to prevent the serious implications of …

The aim of this study was to investigate the kinetics of neutralizing antibodies (NAbs) and
anti-SARS-CoV-2 anti-S-RBD IgGs up to three months after the second vaccination dose …

Purpose As protection from COVID-19 following two doses of the BNT162b2 vaccine
showed a time dependent waning, a third (booster) dose was administrated. This study aims …

Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still
scarce and are important to design vaccination strategies. In this study, 231 healthcare …